DK1092155T3 - Fremgangsmåde til tidlig diagnose af carcinomer - Google Patents

Fremgangsmåde til tidlig diagnose af carcinomer

Info

Publication number
DK1092155T3
DK1092155T3 DK99945931T DK99945931T DK1092155T3 DK 1092155 T3 DK1092155 T3 DK 1092155T3 DK 99945931 T DK99945931 T DK 99945931T DK 99945931 T DK99945931 T DK 99945931T DK 1092155 T3 DK1092155 T3 DK 1092155T3
Authority
DK
Denmark
Prior art keywords
carcinomas
early diagnosis
procedure
overexpression
cell cycle
Prior art date
Application number
DK99945931T
Other languages
Danish (da)
English (en)
Inventor
Knebel Doeberitz Magnus Ch Von
Dimitri Spitkovsky
Original Assignee
Deutsches Krebsforsch
Von Knebel Doeberitz Magnus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforsch, Von Knebel Doeberitz Magnus filed Critical Deutsches Krebsforsch
Application granted granted Critical
Publication of DK1092155T3 publication Critical patent/DK1092155T3/da

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5755Immunoassay; Biospecific binding assay; Materials therefor for cancer of the uterine cervix, uterine corpus or endometrium
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK99945931T 1998-07-01 1999-07-01 Fremgangsmåde til tidlig diagnose af carcinomer DK1092155T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19829473A DE19829473C2 (de) 1998-07-01 1998-07-01 Verfahren zur frühen Diagnose von Carcinomen
PCT/DE1999/002094 WO2000001845A2 (de) 1998-07-01 1999-07-01 Verfahren zur frühen diagnose von carcinomen

Publications (1)

Publication Number Publication Date
DK1092155T3 true DK1092155T3 (da) 2003-03-24

Family

ID=7872684

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99945931T DK1092155T3 (da) 1998-07-01 1999-07-01 Fremgangsmåde til tidlig diagnose af carcinomer

Country Status (22)

Country Link
US (2) US6709832B1 (no)
EP (1) EP1092155B1 (no)
JP (1) JP3404020B2 (no)
KR (1) KR100646193B1 (no)
CN (1) CN1209627C (no)
AT (1) ATE230487T1 (no)
AU (1) AU749769B2 (no)
BR (1) BRPI9912227B8 (no)
CA (1) CA2336153C (no)
CZ (1) CZ292076B6 (no)
DE (2) DE19829473C2 (no)
DK (1) DK1092155T3 (no)
ES (1) ES2190820T3 (no)
HU (1) HUP0102744A2 (no)
IL (1) IL140550A (no)
MX (1) MXPA00012852A (no)
NO (1) NO328685B1 (no)
PL (1) PL198623B1 (no)
RU (1) RU2217761C2 (no)
SK (1) SK284056B6 (no)
TR (1) TR200003903T2 (no)
WO (1) WO2000001845A2 (no)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7306926B2 (en) * 1998-07-01 2007-12-11 Mtm Laboratories Ag Method for detecting carcinomas in a solubilized cervical body sample
AUPP991199A0 (en) * 1999-04-21 1999-05-13 University Of Sydney, The Methods for diagnosing pre-cancerous and cancerous conditions
DE10006033B4 (de) * 2000-02-10 2005-11-10 Professor Dr. Magnus von Knebel Doeberitz Chirurgische Universitätsklinik Sektion für Molekulare Diagnostik und Therapie Immunisierung eines Individuums gegen Carcinome und ihre Vorstufen
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US7408041B2 (en) 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US9249229B2 (en) 2000-12-08 2016-02-02 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
AUPR201500A0 (en) * 2000-12-11 2001-01-11 Biosceptre Pty Ltd Methods for identifying pre-neoplastic and neoplastic states in mammals
DE10063179A1 (de) * 2000-12-18 2002-06-20 Bayer Ag Verfahren zur spezifischen Detektion von Tumorzellen und ihren Vorstufen in Gebärmutterhalsabstrichen durch simultane Messung von mindestens zwei verschiedenen molekularen Markern
JP4384852B2 (ja) * 2001-01-17 2009-12-16 イントリート ピーティーワイ リミテッド 非機能性p2x7レセプター抗体、癌及びその他の容態の診断及び処置
EP1369694A1 (en) * 2002-04-09 2003-12-10 MTM Laboratories AG Method for discrimination of metaplasias from neoplastic or preneoplastic lesions
DE60200248T2 (de) * 2002-08-01 2005-01-27 Mtm Laboratories Ag Verfahren für Lösung-basierte Diagnose
EP1422526A1 (en) 2002-10-28 2004-05-26 MTM Laboratories AG Method for improved diagnosis of dysplasias
WO2004070062A2 (en) * 2003-02-04 2004-08-19 Wyeth Compositions and methods for diagnosing and treating cancers
EP1600513B1 (en) * 2003-02-26 2010-02-24 Sysmex Corporation Method of examining a cell
ATE289685T1 (de) * 2003-08-25 2005-03-15 Mtm Lab Ag Verfahren zum nachweis von karzinomen in solubilisierten zervikalen körperproben
ES2381644T3 (es) * 2004-03-24 2012-05-30 Tripath Imaging, Inc. Métodos y composiciones para la detección de enfermedades de cuello uterino
DE602005024964D1 (de) * 2004-05-31 2011-01-05 Sysmex Corp Verfahren zur beurteilung der malignität einer säuger-krebszelle
EP1628135A1 (en) * 2004-08-20 2006-02-22 MTM Laboratories AG Method for detecting medically relevant conditions in a solubilized LBC sample
US7892750B1 (en) * 2004-12-23 2011-02-22 University Of Notre Dame Du Lac Cathepsin E as a marker of colon cancer
JP4766969B2 (ja) 2005-09-14 2011-09-07 シスメックス株式会社 組織性質判定装置
US7972776B2 (en) * 2005-11-15 2011-07-05 Oncohealth Corporation Protein chips for HPV detection
SG10201400426XA (en) 2006-01-12 2014-07-30 Alexion Pharma Inc Antibodies to ox-2/cd200 and uses thereof
JP2010505426A (ja) * 2006-10-10 2010-02-25 バイオスセプター インターナショナル リミテッド 非機能性p2x7受容体に対する抗体を産生するハイブリドーマ
WO2010129821A1 (en) * 2009-05-07 2010-11-11 Oncohealth Corporation Identification of high grade or ≥cin2 for early stages and late stages detection, screening, and diagnosis of human papillomavirus (hpv) and hpv-associated cancers
US8278056B2 (en) * 2008-06-13 2012-10-02 Oncohealth Corp. Detection of early stages and late stages HPV infection
US8968995B2 (en) * 2008-11-12 2015-03-03 Oncohealth Corp. Detection, screening, and diagnosis of HPV-associated cancers
JP5111902B2 (ja) * 2007-03-14 2013-01-09 シスメックス株式会社 癌の診断支援装置
EP2028600B1 (en) 2007-08-24 2016-10-26 Sysmex Corporation Diagnosis support system for cancer, diagnosis support for information providing method for cancer, and computer program product
ATE542139T1 (de) 2007-09-14 2012-02-15 Biosceptre Int Ltd Purinerge (p2x)-rezeptoren in extrazellulärer körperflüssigkeit
ES2619681T3 (es) 2007-09-14 2017-06-26 Biosceptre (Aust) Pty Ltd Novedosos epítopos P2X7
CN102143978B (zh) 2008-07-04 2015-02-18 生物权威国际有限公司 抗p2x7肽和表位
EP2467404B1 (en) 2009-08-20 2015-09-30 Biosceptre International Limited Anti p2x7 receptor antibodies and fragments thereof
WO2011075789A1 (en) 2009-12-24 2011-06-30 Biosceptre International Limited Antibodies to non-functional oligomeric p2x7 receptors
JP5819851B2 (ja) 2010-01-08 2015-11-24 オンコヘルス コーポレーション Hpv関連の癌の治療及びスクリーニングのための細胞に基づいた高処理能力hpv免疫アッセイ
US8900813B2 (en) 2010-08-17 2014-12-02 Medical Diagnostic Laboratories, Llc CIP2A as a biomarker in detection of cervical cancer
EP2613808B1 (en) 2010-09-10 2017-11-08 Biosceptre (Aust) Pty Ltd Companion animal cancer treatments with an anti p2x7 antibody
US9551700B2 (en) 2010-12-20 2017-01-24 Milagen, Inc. Device and methods for the detection of cervical disease
MX349321B (es) 2011-07-01 2017-07-21 Biosceptre (Aust) Pty Ltd Terapia combinada.
EP2773390B1 (en) 2011-11-03 2020-12-30 Tripath Imaging, Inc. Methods and compositions for preparing samples for immunostaining
AU2012340441A1 (en) * 2011-11-15 2014-05-29 University Of Miami Methods for detecting human papillomavirus and providing prognosis for head and neck squamous cell carcinoma
US11761963B2 (en) 2017-09-27 2023-09-19 Alexion Pharmaceuticals, Inc. Biomarker signature for predicting tumor response to anti-CD200 therapy
WO2019234176A1 (en) 2018-06-07 2019-12-12 Universitaet Des Saarlandes Novel biomarkers for carcinoma diagnosis
CN108893534A (zh) * 2018-06-26 2018-11-27 华中科技大学鄂州工业技术研究院 泛癌症诊断标记物
RU2707884C1 (ru) * 2018-10-03 2019-12-02 федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) (ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Се Способ ранней диагностики почечно-клеточной карциномы по наличию антител к зрительному аррестину
FR3088640A1 (fr) 2018-10-14 2020-05-22 Smart Diagnostix Pharma Nouveau polypeptide se liant specifiquement a la proteine p16
CN111257565A (zh) * 2018-12-03 2020-06-09 上海细胞治疗集团有限公司 一种衰老细胞的检测试剂盒及其检测方法
CN113295683A (zh) * 2021-05-24 2021-08-24 烟台海关技术中心 过氧化苯甲酰检测方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
US5268463A (en) * 1986-11-11 1993-12-07 Jefferson Richard A Plant promoter α-glucuronidase gene construct
PT665886E (pt) 1992-10-16 2003-10-31 Cold Spring Harbor Lab Rearranjo de complexos de ciclina e suas utilizacoes
WO1994012881A2 (en) * 1992-12-02 1994-06-09 Hochstrasser Denis F A METHOD FOR DETECTING GROWING CELLS USING TRANSLATIONALLY CONTROLLED TUMOR PROTEIN p21
US5543291A (en) * 1993-01-29 1996-08-06 Dana Farber Cancer Institute Method of detecting carcinoma
US6316208B1 (en) * 1994-01-07 2001-11-13 Memorial Sloan-Kettering Cancer Center Methods for determining isolated p27 protein levels and uses thereof
RU2164419C2 (ru) * 1994-03-18 2001-03-27 Мириад Дженетикс, Инк. Ген mts, мутации данного гена и способы диагностики злокачественных опухолей с использованием последовательности гена mts
CA2162150C (en) * 1994-03-18 2010-03-30 Mark H. Skolnick Germline mutations in the mts gene and method for detecting predisposition to cancer at the mts gene
US5763190A (en) * 1994-09-21 1998-06-09 The Trustees Of The University Of Pennsylvania Methods for the identification of compounds capable of inducing the nuclear translocation of a receptor complex comprising the glucocoticoid receptor type II and viral protein R interacting protein
US6033847A (en) * 1995-02-06 2000-03-07 St. Jude Children's Research Hospital InK4c-p18 and InK4d-p19, inhibitors of cyclin-dependent kinases CDK4 and CDK6, and uses thereof
US5976799A (en) 1996-03-21 1999-11-02 The Board Of Trustees Of The University Of Arkansas Early detection of ovarian carcinoma using P16 gene products
US5851797A (en) * 1996-06-19 1998-12-22 Regeneron Pharmaceuticals, Inc. Tie ligand-3, methods of making and uses thereof
US5858683A (en) * 1996-08-30 1999-01-12 Matritech, Inc. Methods and compositions for the detection of cervical cancer
WO2000024245A1 (en) * 1998-10-28 2000-05-04 President And Fellows Of Harvard College REGULATION OF TH2 CELL ACTIVITY BY MODULATION OF NFATp AND NFAT4 ACTIVITY

Also Published As

Publication number Publication date
BRPI9912227B8 (pt) 2021-07-06
KR20010074632A (ko) 2001-08-04
SK20312000A3 (sk) 2001-10-08
RU2217761C2 (ru) 2003-11-27
US6709832B1 (en) 2004-03-23
PL345407A1 (en) 2001-12-17
JP2002519681A (ja) 2002-07-02
IL140550A (en) 2005-08-31
HUP0102744A2 (hu) 2001-11-28
CA2336153C (en) 2005-12-20
PL198623B1 (pl) 2008-07-31
CZ20004922A3 (cs) 2001-07-11
AU749769B2 (en) 2002-07-04
ATE230487T1 (de) 2003-01-15
US20030152993A1 (en) 2003-08-14
EP1092155B1 (de) 2003-01-02
DE59903915D1 (de) 2003-02-06
CZ292076B6 (cs) 2003-07-16
JP3404020B2 (ja) 2003-05-06
CN1307681A (zh) 2001-08-08
EP1092155A2 (de) 2001-04-18
SK284056B6 (sk) 2004-08-03
WO2000001845B1 (de) 2000-04-20
NO328685B1 (no) 2010-04-26
NO20006681D0 (no) 2000-12-28
ES2190820T3 (es) 2003-08-16
DE19829473A1 (de) 2000-01-13
NO20006681L (no) 2001-02-26
BRPI9912227B1 (pt) 2013-08-20
CA2336153A1 (en) 2000-01-13
IL140550A0 (en) 2002-02-10
HK1038609A1 (zh) 2002-03-22
BRPI9912227A (pt) 2001-04-24
DE19829473C2 (de) 2000-08-10
AU5848799A (en) 2000-01-24
CN1209627C (zh) 2005-07-06
TR200003903T2 (tr) 2001-06-21
WO2000001845A3 (de) 2000-02-17
MXPA00012852A (es) 2003-09-11
WO2000001845A2 (de) 2000-01-13
KR100646193B1 (ko) 2006-11-17

Similar Documents

Publication Publication Date Title
DK1092155T3 (da) Fremgangsmåde til tidlig diagnose af carcinomer
DE60228557D1 (de) Candida-nachweis
DE60300339D1 (de) Verfahren zum Nachweis von Karzinomen in solubilisierten zervikalen Körperproben
TR200001460T2 (tr) Çok düşük estrojen dozları kullanılarak menopoz sonrası kadınların tedavisine yönelik metodlar
CY1112330T1 (el) Πρωτεϊνες συνδεσης gag
DE69937835D1 (de) Antikörper für apoptosemarker und anwendungsverfahren
WO2000008464A3 (de) Verfahren zur bestimmung der immunabwehr des blutes sowie testkit hierfür
SE9604815D0 (sv) A metod of diagnosis
DE69821246D1 (de) Testverfahren für collagenpeptid
WO2002021133A3 (en) Methods of detecting cancer based on prostasin
FI973561A7 (fi) Menetelmä ja yhdisteitä analysoitavien aineiden määrittämiseksi remane nssimittausten avulla ja mainittujen yhdisteiden käyttö
EA200200435A1 (ru) Анализ лептина
ATE274190T1 (de) Methoden und kits zum sequenzieren von polypeptiden
PT918991E (pt) Metodo de ensaio
EP2071338A3 (en) Human diabetes-mediating proteins
ATE275268T1 (de) Verfahren zur diagnose von sjögren-syndrom
DK1386160T3 (da) Fremgangsmåde til påvisning af blodcelle-antigener og antistoffer rettet mod disse
SE0002835D0 (sv) Method and kit for production of monoclonal antibodies
IL129236A0 (en) Monoclonal antibodies against a human act and serine protease complex
SE9602234D0 (sv) A novel diagnostic method utilizing ECP, and reagents to be used in the methods
DK1171157T3 (da) Anvendelse af glucose-6-phosphat-isomerase og antistoffer derimod til diagnosticering og behandling af arthritis, og test for anti-arthritis-forbindelser
DK0929812T3 (da) Diagnosehjælpemiddel samt fremgangsmåde til påvisning af drægtighed af drøvtyggere
IL141858A0 (en) Diagnostic method for detecting disturbances of the pancreas
EP1702984A3 (en) A method for detecting prostate cancer
WO2001006226A3 (de) Verfahren zur bestimmung der proliferationsaktivität von zellen